Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.59 |
| ▸ | AURKA | O14965 | 7/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | ITK | Q08881 | 1/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | GRK2 | P25098 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381231 | 0.92 | AURKA (0.59) | TTKAURKAMAPK1MAPK3NAMPT | |
| SCHEMBL5801198 | 0.92 | MAPK1 (0.53) | TTKAURKAMAPK1MAPK3NAMPT | |
| SCHEMBL5803362 | 0.89 | NPC1 (0.53) | TTKAURKAMAPK1NAMPTMAP2K4 | |
| SCHEMBL5785886 | 0.89 | AURKA (0.66) | TTKAURKAMAPK1ITKMAP2K4 | |
| SCHEMBL5783999 | 0.87 | AURKA (0.57) | TTKAURKAMAPK1ITKMAP2K4 | |
| SCHEMBL5379163 | 0.86 | TTK (0.67) | TTKAURKAMAP2K4AURKB | |
| SCHEMBL5799963 | 0.85 | TTK (0.56) | TTKAURKAMAPK1MAPK3MAP2K4 | |
| SCHEMBL5383159 | 0.85 | MAPK1 (0.54) | TTKAURKAMAPK1MAPK3NAMPT | |
| SCHEMBL5377426 | 0.84 | TTK (0.68) | TTKAURKAMAPK1MAPK3MAP2K4 | |
| SCHEMBL10269652 | 0.84 | NAMPT (0.70) | TTKAURKAMAPK1MAPK3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | TTK 1198/4885AURKA 3307/4885MAPK1 1/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | TTK 2139/4885AURKA 2787/4885MAPK1 2816/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | TTK 714/4885AURKA 1439/4885MAPK1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.